Zacks Investment Research downgraded shares of PLx Pharma Inc (NASDAQ:PLXP) from a buy rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

Several other equities research analysts have also weighed in on PLXP. UBS AG upgraded shares of PLx Pharma from a market perform rating to an outperform rating and set a $12.00 target price on the stock in a report on Monday, July 31st. Redburn Partners upgraded shares of PLx Pharma to an outperform rating in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $9.63.

Shares of PLx Pharma (NASDAQ:PLXP) traded down 1.3577% during mid-day trading on Tuesday, reaching $6.3501. 2,273 shares of the company’s stock traded hands. PLx Pharma has a 52 week low of $5.60 and a 52 week high of $126.72. The company’s 50 day moving average is $6.53 and its 200-day moving average is $7.55. The firm’s market cap is $55.17 million.

ILLEGAL ACTIVITY WARNING: “PLx Pharma Inc (PLXP) Downgraded by Zacks Investment Research” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new stake in PLx Pharma in the second quarter worth $1,413,000. University of Texas Investment Managment Co. acquired a new stake in PLx Pharma in the second quarter worth $385,000. Finally, Heritage Way Advisors LLC acquired a new stake in PLx Pharma in the second quarter worth $197,000. Institutional investors own 19.68% of the company’s stock.

About PLx Pharma

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related stocks with our FREE daily email newsletter.